Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06478017 · ClinicalTrials.gov registry record · Phase 2
Belatacept in Heart Transplantation
A Phase 2 study of Heart Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT06478017: Recruiting Phase 2 study of Heart Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06478017 is a Phase 2 study of Heart Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 66 participants, below the 8,525-participant average among 12 other Heart Transplant trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06478017, a Phase 2 study of Heart Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months post-transplant. Both study arms will receive CellCept® (mycophenolate mofetil- MMF) or Myfortic® (mycophenolate sodium). Corticosteroids will be continued throughout the study in the belatacept arm. The primary objective is to evaluate whether NULOJIX® (belatacept), when implemented with gradual tacrolimus withdrawal over 9 months, is safe with respect to preventing the composite endpoint of acute cellular rejection (ACR) \>= International Society of Heart and Lung Transplantation (ISHLT) 2R, hemodynamic compromise rejection in the absence of a biopsy or histological rejection, re-transplantation, and death at 18 months post-transplant.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Tacrolimus
- DRUG Belatacept
- DRUG Mycophenolate Mofetil/Sodium
Study Locations (4)
California
- Cedars Sinai Heart Institute/ Cedars Sinai Medical (Site # 71146) - Los Angeles
Florida
- Tampa General Hospital (Site # 71150) - Tampa
New York
- NYU Langone Health (Site # 71177) - New York
Utah
- University of Utah Medical Center (Site # 71126) - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
What NCT06478017 shows while recruiting
NCT06478017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 8,525-participant average among 12 other Heart Transplant trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heart Transplant appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT06478017 reports a single indexed study location in California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06478017 about?
NCT06478017 is a clinical study titled "Belatacept in Heart Transplantation". This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months ...
What is the current status of trial NCT06478017?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2025-01-29. Estimated completion is 2028-01-31.
What conditions does trial NCT06478017 study?
This clinical trial studies the following conditions: Heart Transplant.
What interventions are being tested in trial NCT06478017?
The interventions under investigation include: Prednisone (DRUG), Tacrolimus (DRUG), Belatacept (DRUG), Mycophenolate Mofetil/Sodium (DRUG).
Who is sponsoring clinical trial NCT06478017?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06478017 being conducted?
This trial has 4 study locations across California, Florida, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06478017's enrollment target sits among peer trials
66 11th of 12 higher than 2 of 12 other Heart Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
US National OCS Heart Perfusion (OHP) Registry
RECRUITING
-
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
RECRUITING · NA
-
Enhancing Heart Allograft Function With the OCS Heart System Trial
RECRUITING · NA
-
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI